Off-Label Treatment With Immune Checkpoint Inhibitor Blockade (NCT07754292)

🧪 Interventions in This Study

• One or more off-label ICIs alone or with other on-label ICI(s) (DRUG)
• Off-label ICI(s) with targeted therapy (DRUG)
• off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (866) 680-0505

Email: cccto@mcw.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Malignancy

• The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease — Toronto, Ontario
• Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects — Anchorage, Alaska
• BostonGene-Integrated Genomic Registry (BIGR) — Waltham, Massachusetts
• Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository — Boston, Massachusetts

Explore by condition: All Malignancy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.